A compound that kills specific lymphoma cells has been discovered by an international research team, co-led by the OCI (Ontario Cancer Institute), Canada. This discovery will speed up the development of targeted medications to fight the most common forms of non-Hodgkin’s lymphoma. You can read about this in the online journal Cancer Cell (DOI 0.1016/j.ccr.2009.12.050)… Read Full Article

ChemGenex Pharmaceuticals announces that the U.S. Food and Drug Administration’s (FDA) Office of Oncology Drug Products has issued a complete response letter regarding the new drug application (NDA) for OMAPRO™ (omacetaxine mepesuccinate) for the treatment of adults with chronic myeloid leukemia (CML) who have failed prior therapy with imatinib and have the Bcr-Abl T315I mutation… Read...

Leukemia related protein 16 (LRP16) gene is an important estrogen-responsive gene. LRP16 gene plays an important role in the carcinogenesis and progression of hormone-dependent cancer. LRP16 expression was also reported to be associated with invasion, metastasis and prognosis of gastric carcinoma. But no comprehensive description of LRP16 protein expression in colorectal cancer has been reported… Read...

In the past decade, researchers have made dramatic strides in understanding and treating leukemia, according to the April issue of Mayo Clinic Health Letter. Leukemia encompasses several types of cancer of the bone marrow and blood. While often associated with children and young adults, leukemia most commonly occurs in adults over age 60… Read Full Article

Researchers from the Children’s Cancer Hospital at The University of Texas M. D. Anderson Cancer Center may have found a way to more accurately predict treatment outcomes in young leukemia patients using information from a common and simple complete blood count test, also known as a CBC… Read Full Article

Seattle Genetics, Inc. (NASDAQ:SGEN), Takeda Pharmaceutical Company Limited (TOKYO:4502) and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced the initiation of a phase III clinical trial of brentuximab vedotin (SGN-35) for post-transplant Hodgkin lymphoma patients… Read Full Article

TrovaGene, Inc. (TROV.PK), formerly Xenomics, Inc. (XNOM… Read Full Article

TrovaGene, Inc. (TROV.PK), formerly Xenomics, Inc. (XNOM… Read Full Article

TrovaGene, Inc. (TROV.PK), formerly Xenomics, Inc. (XNOM… Read Full Article

TrovaGene, Inc. (TROV.PK), formerly Xenomics, Inc. (XNOM… Read Full Article